Capricor Therapeutics, Inc. (CAPR) P/S ratio

P/S ratio · fiscal 2024
21.8×

The P/S ratio of Capricor Therapeutics, Inc. (CAPR) was 21.8× at the end of fiscal 2024 (December 31, 2024). That is 319.6% higher than the 5.2× of fiscal 2023. Figures as of 18 Nov 2026, 04:19 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio, fiscal 2024
21.8×
Change on fiscal 2023
+319.6%
Highest on record
276.2×fiscal 2021
Lowest on record
4.7×fiscal 2019
Fiscal years on record
92016–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Capricor Therapeutics, Inc. P/S ratio, in more detail

Across the 9 fiscal year-ends on record (2016–2024), the highest was 276.2× in fiscal 2021 and the lowest 4.7× in fiscal 2019.

History · 9 fiscal years

P/S ratio at each fiscal year-end

Capricor Therapeutics, Inc. P/S ratio, year by year

Capricor Therapeutics, Inc. (CAPR) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
2025——$28.86—
202421.8× 319.6% up$13.80$0.63
20235.2× 86.0% down$4.89$0.94
202237.1× 86.6% down$3.86$0.10
2021276.2× 60.5% up$2.93$0.01
2020172.1× 3,542.0% up$3.43$0.02
20194.7× 34.5% down$1.28$0.27
20187.2× 54.5% down$4.10$0.57
201715.9× 28.6% up$15.80$1.00
201612.3×—$26.60$2.16
2015——$30.70—
2014——$37.50—
2013——$32.50—
2012——$25.00—
2011——$275.00—
2010——$310.00—
2009——$605.00—
2008——$425.00—
2007——$2,750.00—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on CAPR

Capricor Therapeutics, Inc., figure by figure

Capricor Therapeutics, Inc. (CAPR) overview: price, valuation and scorecard

Capricor Therapeutics, Inc. P/S ratio: questions and answers

What is Capricor Therapeutics, Inc.'s P/S ratio?

The P/S ratio of Capricor Therapeutics, Inc. (CAPR) was 21.8× at the end of fiscal 2024 (December 31, 2024). That is 319.6% higher than the 5.2× of fiscal 2023.

What are the highest and lowest P/S ratio figures on record for Capricor Therapeutics, Inc.?

Across the 9 fiscal year-ends on record (2016–2024), the highest was 276.2× in fiscal 2021 and the lowest 4.7× in fiscal 2019.

How is Capricor Therapeutics, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Capricor Therapeutics, Inc. (CAPR) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CAPR/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.